** Drug developer Sage Therapeutics' shares fall 4.3% to $4.70 premarket ** Company says it will stop further development of its experimental drug, dalzanemdor, after it did not meet main goal in a mid-stage trial
** Sage was testing the drug to treat cognitive impairment associated with Huntington's disease, which causes nerve cells in the brain to decay over time
** 2 of 20 brokerages rate the stock "buy", 16 "hold" and 2 "sell"; median PT $9 - LSEG
** As of last close, stock down 77.3% YTD
(Reporting by Kamal Choudhury in Bengaluru) ((Kamal.Choudhury@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.